Anti-inflammatory agents as modulators of the inflammation in adipose tissue: A systematic review

Sara Sayonara da Cruz Nascimento1, Jaluza Luana Carvalho de Queiroz2, Amanda Fernandes de Medeiros2, Ana Clara de França Nunes2, Grasiela Piuvezam3,4, Bruna Leal Lima Maciel1,6, Thaís Souza Passos1,5, Ana Heloneida de Araújo Morais1,2,5*

1 Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, Brazil, 2 Biochemistry and Molecular Biology Postgraduate Program, Biosciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil, 3 Public Health Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal/RN, Brazil, 4 Department of Public Health, Center for Health Sciences, Postgraduate Program in Public Health, Federal University of Rio Grande do Norte, Natal/RN, Brazil, 5 Department of Nutrition, Federal University of Rio Grande do Norte, Natal, RN, Brazil

* aharaujomorais@gmail.com, ana.morais@ufrn.br

Abstract

Obesity is characterized by an adipose tissue mass expansion that presents a risk to health, associated with a chronic increase in circulating inflammatory mediators. Anti-inflammatory agents are an obesity alternative treatment. However, the lack of effective agents indicates the need to assess the mechanisms and identify effective therapeutic targets. The present work identified and described the mechanisms of action of anti-inflammatory agents in adipose tissue in experimental studies. The review was registered in the International Prospective Registry of Systematic Reviews (PROSPERO—CRD42020182897). The articles’ selection was according to eligibility criteria (PICOS). The research was performed in PubMed, ScienceDirect, Scopus, Web of Science, VHL, and EMBASE. The methodological quality evaluation was assessed using SYRCLE. Initially, 1511 articles were selected, and at the end of the assessment, 41 were eligible. Among the anti-inflammatory agent classes, eight drugs, 28 natural, and five synthetic compounds were identified. Many of these anti-inflammatory agents act in metabolic pathways that culminate in the inflammatory cytokines expression reduction, decreasing the macrophages infiltration in white and adipose tissue and promoting the polarization process of type M1 to M2 macrophages. Thus, the article clarifies and systematizes these anti-inflammatory agents’ mechanisms in adipose tissue, presenting targets relevant to future research on these pathways.

Introduction

Obesity is a growing public health problem that has reached pandemic proportions [1]. According to the World Health Organization (WHO) data, the number of people with this comorbidity has shown significant and constant growth, tripling in the last 20 years [2].
Obesity is characterized by an expansion of adipose tissue and changes in body distribution. This accumulation is associated with a chronic increase in circulating concentrations of inflammatory mediators, including several acute-phase inflammatory proteins, pro, and inflammatory cytokines, adhesion molecules, and pro-thrombotic molecules, resulting in a low-grade, chronic local, and systemic inflammation [3–7].

The normal adipose tissue (AT) also forms about 10–15% of the macrophages. These cells are classified into two types, with an anti-inflammatory phenotype predominant in healthy AT, called M2 or "alternatively activated." However, in humans and rodents with obesity, there is a considerable macrophage infiltration in response to the local release of monocyte chemoattractant protein-1 (MCP-1). Thus, in the state of obesity, macrophages make up about 50% of the population of interstitial cells, and their phenotype is changed to a pro-inflammatory state, called M1 or "classically activated [8–10]. These macrophages are characterized by the secretion of pro-inflammatory cytokines, resulting in tissue inflammation, and inducing several pathological effects [8].

The classic pro-inflammatory responses of M1 macrophages are dependent on toll-like receptors (TLRs) and on the activation of nuclear factor kappa B/c-Jun N-terminal kinases (NFκB/JNK), involving the phosphorylation of the I kappa B kinase (IκB) inhibitor by the IκB kinase complex (IKK-α, IKK-β, and IKK-γ), and inducing the production of inflammatory cytokines [11, 12]. Conversely, the activation of M2 macrophages leads to the recruitment of peroxisome proliferator-activated gamma receptor (PPAR-γ) or other transcription factors, resulting in an anti-inflammatory state [13–15].

Oxidative stress results from increased reactive oxygen species (ROS) production and causes tissue damage and pathological conditions, such as inflammation [16, 17]. This increase has been associated with increased pro-inflammatory cytokines in white adipose tissue (WAT) and reduced adiponectins [16]. Oxidative stress can cause damage by increasing the expression of Akt, extracellular signal-regulated kinase (ERK), signal transducers and activators of transcription (STAT), and JNK, which have been identified as proteins promoting pathologies, including inflammation [17–19].

This scenario leads to a pro-inflammatory state caused by the production of cytokines as a tumor necrosis factor-alpha (TNF-α), through the activation of the nuclear factor kappa B (NF-κB), as well as interleukin 6 (IL-6) [20–22]. The increase in TNF-α and WAT also favors lipolysis and the release of free fatty acids in the plasma, which triggers lipotoxicity and promotes the development of several diseases mediated by ROS. WAT dysfunction can also alter the expression of transcription factors involved in lipid metabolisms, such as sterol regulatory element-binding proteins (SREBP-1c) and PPAR-γ [23–26].

The treatments used for obesity depend mainly on changes in eating habits and lifestyle, being combined, when necessary, with pharmacotherapy and major surgery aiming at weight loss [27]. Drug use is recommended in patients who do not correspond to the changes above mentioned in the first six months and have some chronic disease induced by obesity [28–30]. In these cases, anti-inflammatory agents are presented as an alternative treatment, being studied both in vitro and in vivo in experimental models and clinical trials [31–33].

Thus, the search for strategies aimed at treating inflammation in adipose tissue requires the analysis of the specific mechanisms of action of each treatment used, seeking to direct them more effectively for their use in humans. Therefore, several animal models that share characteristics of human obesity are used to adapt the development of new treatments. According to Lutz [34], although no model recapitulates all aspects of human obesity and its comorbidities, rodent models allow the view of specific mechanisms, being extremely useful to direct the means of treatment through specific pathways. Thus, considering that this systematic review has as its primary objective to evaluate the mechanisms of action of anti-inflammatory agents...
in obesity and to indicate effective ways in its treatment, only articles with animal models were chosen to expand them in greater detail precision for future clinical studies.

It is also essential to emphasize that the treatment of obesity does not necessarily have to focus on weight loss, considering that up to a third of people with obesity do not have cardio-metabolic abnormalities, being defined as patients with metabolically healthy obesity. These patients also have lower levels of inflammatory markers. Thus, treating inflamed tissue in people with obesity is a strategy for improving their health and quality of life [35].

In this perspective, considering the inflammatory aspect, the primary treatment for obesity would be to slow the growth and expansion of adipocytes [36]. In addition to drugs, several bioactive compounds from plants and synthetics have been commonly used to treat obesity regarding action on adipose tissue. These compounds have anti-inflammatory properties and play a fundamental role in treating obesity through their antioxidant and anti-inflammatory properties [37]. The anti-inflammatory action can be achieved by consuming a diet with antioxidant nutrients that reduce ROS levels and components that induce an inflammatory response [38]. However, studies are still needed to assess the effectiveness and selectivity, understanding the different mechanisms of anti-inflammatory agents regarding their functionality in excess adipose tissue [39].

Given the above and considering the search for new alternatives for treating obesity and its direct correlation with inflammation, it is necessary to understand what mechanisms are involved in these compounds’ actions in adipose tissue to improve experimental and clinical studies. Thus, the present study aimed to gather the scientific literature on the subject through a systematic review to answer the following question: "What are the mechanisms of action of anti-inflammatory agents in adipose tissue?"

**Methodology**

This systematic review was prepared following the methodological criteria established by the Items of Preferred Reports for Systematic Reviews and Meta-Analysis (PRISMA) [40] and the guidelines of the Systematic Review Center for Animal Laboratory Experimentation–SYRCLE [41].

The protocol for constructing the systematic review was registered in the International Prospective Registry of Systematic Reviews in progress—PROSPERO, under CRD42020182897. The protocol was described by Nascimento et al. [42].

**Search strategy**

Searches for articles were performed through electronic searches in January 2022 in PubMed, ScienceDirect, Scopus, Web of Science, Virtual Health Library (VHL), and EMBASE. The databases’ searches were performed through the CAPES Journal Portal of Brazil, with a login from the Federal University of Rio Grande do Norte. Searches were performed according to the strategy described in Table 1.

**Inclusion and exclusion criteria**

**Inclusion criteria.** Original studies were conducted on male rats and mice with overweight or obesity, presenting a control group and treatment with anti-inflammatory agents, drugs, nutraceuticals, and bioactive compounds.

---

Table 1. Research strategy equation to search for articles in databases to answer the question: What are the action mechanisms of anti-inflammatory agents in adipose tissue?

| Database          | PUBMED | SCOPUS | SCIENCE DIRECT | WEB OF SCIENCE | BVS   | EMBASE |
|-------------------|--------|--------|----------------|----------------|-------|--------|
| **Search Strategy** |        |        |                |                |       |        |
| Inflammation and "adipose tissue" and "Anti-inflammatory agents" and obesity |        |        |                |                |       |        |

https://doi.org/10.1371/journal.pone.0273942.t001
Exclusion criteria. Articles that did not describe the mechanism of action, frequency, dose, and time of the experiment were excluded, in addition to documents that were not scientific articles, case reports, and reviews.

Data extraction process
The studies were initially selected by reading titles, abstracts, and keywords. With Rayyan QCR [43], a specific online server for systematic reviews and references was managed with Mendeley software [44]. A complete reading of the text was then performed to analyze the defined inclusion and exclusion criteria.

The complete reading of the text was performed for data extraction: bibliographic (author, year of publication, and type of study), experimental design (number and type of control groups), characteristics of the animal model (species, lineage, sex, weight, age), exposure (oral diet, time of the experiment, anti-inflammatory used and its mechanism of action, dosage, time of administration, frequency of administration, type of administration and vehicle), and statistical measures used.

The following outcomes were assessed: reduction of inflammatory markers such as body fat, gene expression, and cytokine levels, such as IL-1, IL-6, IL-8, TNF-alpha, leptin, resistin, and inhibition of the cyclooxygenase enzyme (COX-2), induced nitric oxide synthase (iNOS), increased adiponectin levels, reduced expression of the enzyme 5-lipoxygenase (5-LOX), sensitivity to insulin, and reduced PCR.

Risk of bias and quality evaluation
After reading the articles included in the review, a qualitative methodological assessment was carried out using the SYRCLE [41] Protocol, assessing the risk of bias in experimental studies. The tool has ten questions, with items punctuated with "yes," indicating a low risk of bias, "no," indicating a high risk of bias, or "not clear," indicating uncertain risk. The reviewers were previously trained and calibrated, ensuring greater uniformity in the evaluation, using Cohen's kappa agreement coefficient.

Results and discussion
Selection and characteristics of the studies
Several search strategies were tested to find the best answer to the starting question. Thus, a single strategy was used for all bases, considering that the others were very comprehensive or restricted when evaluating the results obtained. A similarity was observed when comparing the results obtained in the articles between the bases. This confirms that the strategy covered the requirements and had a better effect when compared to the others.

Initially, 1512 articles were obtained using the search and manual search strategy, 560 of which were duplicated and, therefore, 952 studies for the title and abstract analysis, resulting in 280 articles selected for a complete reading of the text (Fig 1).

Among the excluded articles (Fig 1), 83 did not discuss the mechanism related and had gaps when presenting their results. Many were performed on cells (52), humans (30), other organs and tissues (26), and evaluated serum/plasma dosages (16), not using any intervention (15), treating other diseases (8), or were a review (1). Thus, considering this systematic review’s objectives, 41 experimental studies developed in animals and using anti-inflammatory compounds (drugs, natural compounds, and synthetic compounds) were included.

The data were classified as heterogeneous, considering that, although the compounds could be grouped into specific classes, they differed. In addition, the studies used animals with
different lineages and genetic changes. Various dosage forms of the selected markers were observed at different frequencies and follow-up times. Data also presented other measures, formats, and the absence of important information. Thus, it became impracticable to perform a meta-analysis.

Risk of bias and quality evaluation

The trained and calibrated reviewers, ensuring uniformity in the evaluation, presented a Cohen’s kappa concordance coefficient ranging from 0.4 to 1.00. The articles’ methodological quality and risk of bias were assessed using the SYRCLE tool (Fig 2).
No study showed clarity regarding using methods to generate a random allocation sequence (Q1 = uncertain risk of 100% bias) considering the selection bias. All articles presented baseline characteristics and showed animals’ pairing in specific groups (Q2 = 100%). However, none was clear about the evaluators’ blinding to avoid predicting the results (Q3 = uncertain risk of bias 100%). Approximately half of the studies showed the random allocation of animals during the experiment (Q4 = 48.8%), and none declared the researchers’ blindness regarding the treatment for each group (Q5 = 100% uncertain risk of bias).

Regarding the analysis of the results (Q6 and Q7), only two articles reported the random selection of animals, and no article described whether there was the evaluator’s blinding (Q7 = uncertain risk of 100% bias). Most studies did not adequately address data on incomplete results, presenting a high risk of bias (Q8 = 70.7%). Most articles were free from biased reporting of results (Q9 = 73.2%), and no other potential sources of bias were found (Q10 = 75.6%).

The articles selected for the systematic review were ordered by compound: pharmaceuticals, natural and synthetic compounds, in decreasing order according to the SYRCLE score, ranging from 5.5 to 7.5 (Table 2).
Table 2. Characteristics of the studies selected for the systematic review separated by categories of anti-inflammatory agents, revealing the outcomes to answer the question: What are the mechanisms of action of anti-inflammatory agents in adipose tissue?

| Author               | Compound/Dose and frequency | Time   | Animals/Species         | Outcomes                                                                 |
|----------------------|----------------------------|--------|-------------------------|--------------------------------------------------------------------------|
| Hsieh et al. [45]    | Colecoxib—30 mg/kg/day     | 12 weeks | Sprague-Dawley Rats     | × COX-2 | Adipocyte hypertrophy | CD68 | TNF-α | PPAR-γ and CEBP-α |
| Ma et al. [46]       | Dextran– 5 mg/kg/day       | 24 h   | C57BL/6j mice           | [CLS] | MCP-1 | [TNF-α, IL-6] | [NF-kB] |
| Ndisang & A. Jadhav [47] | Hemin—30 mg/kg/day       | 8 weeks | Zucker-lean (ZL) and ZDF rats | @ AMPK | SREBP1c and FAS | TNF-α | PPAR-γ | MCR-1 | p65 NF-kB, IKK-α/β | GLUT-4 |
| Furuya et al. [12]   | Atorvastatin—0.1% chow (wt/wt) | 4 weeks | CD11b mice              | [IL-1β] | TNF-α, IL-6 | MCP-1 | CD11b, F4/80, iNOS, CD11c | CD206 © NF-kB, p38, AMPK |
| Okada et al. [48]    | Pioglitazone (TZD) - 0.001% chow | 4 weeks | KKAY mice               | [LXB4, IL-10, IL-13 e Arg-1] | Prostaglandin 2 |
| Xu et al. [49]       | Empagliflozin (TZD) - 3 or 10 mg/kg/day | 16 weeks | C57BL/6j mice           | @ AMPK | Adiponectin, UCP-1 | F4/80, leptina, CLS | × SGLT2 |
| Prabhu et al. [50]   | Dextran– 0.1, 0.7, or 5 mg/kg/day | 4 weeks | C57BL/6j mice           | [IL-6, TNF-α, IL-1β, CD68, CD11c, CCR2, CCR5, F4/80, CCL3 and CCL5] | C57BL/6j mice |
| Zhou et al. [51]     | (EX-4)2-Fc, an GLP-1 receptor agonist—1.8 mg/ kg^3 | 14 days | C57BL/6j mice           | [IL-6] | TNF-α, MCP-1 | CD11b, F4/80, iNOS, CD11c | CD206 © NF-kB, p38, AMPK |
| Lee et al. [52]      | Metaboloid β: (MetA), verabna and hibiscus—50 or 100 mg/kg/day | 8 weeks | C57BL/6j mice           | [PPAR-γ e CEBP-α, SREBP1c and FAS] | TNF-α | PPAR-γ | MCR-1 | p65 NF-kB, AMPK |
| Fenni et al. [53]    | Lycopene and tomato powder supplementation—10 mg/kg of chow/day | 12 weeks | C57BL/6j mice           | [IL-4, CD206, ARG1, CD163] | M1/M2 reason |
| Abu Bakar et al. [54] | Celastrol—1 or 3 mg/kg/day | 8 weeks | Sprague-Dawley rats     | [IL-6, TNF-α, MCP-1, NF-kB, iNOS, CD11c] | Arg1 |
| Alsaggar et al. [55] | Silibinin—50 mg/kg twice a week | 8 weeks | C57BL/6j mice           | [F4/80, CD11c, TNF-α, IL-1β] | IL-10, adiponectin |
| Han et al. [56]      | Berberine—1.5 mg/kg/day    | 12 weeks | C57BL/6j mice           | [F4/80, IL-6, MCP-1] | [IL-4, CD206, ARG1, CD163] |
| Choi, et al. [57]    | Indole-3-carbinol (13C) - 0.1% (wt/wt) | 10 weeks | C57BL/6N mice           | [SIRT-1, PGC-α, UCPI and UCPI3 xERK] | [IL-6] | TNF-α, MCP-1 | CD11c, FAS, UCP-1 | GPR120, PPARγ |
| Ma et al. [58]       | Spermidine—20 mg/kg        | 8 weeks | C57BL/6j mice           | [SREBF1c, FAS, PPARγ, IL-1β, IL-6, iNOS, MCP-1, CCL5, leptin] | F4/80, IL-6, MCP-1 |
| Wei et al. [59]      | EPA e DHA—1, 2 and 4% chow (w/w) | 12 weeks | C57BL/6j mice           | [IL-6, TNFα, MCP-1, CD11c, FAS, UCP-1] | GPR120, PPARγ |
| Cho et al. [60]      | Carvacrol—0.1% chow (w/w)  | 10 weeks | C57BL/6N mice           | [TNFα, IFNα] | [TLR2, TLR4, Tirap, TRAF6, IFNβ, MyD88 and TRIF] |
| Lee et al. [61]      | Black Raspberry Seed Oil—50 ou 100% chow | 10 weeks | C57BL/6 and C57BL/KsJ-db/db mice | [TLR4, NF-κB] | TNFα and IL-6 | F4/80, CD68 and MCP-1 |
| Kim et al. [62]      | Resveratrol—0.4%—400 mg/kg | 10 weeks | C57BL/6j mice           | [TNFα, IFNα, INFα and IL-6] | [TLR2, TLR4, MyD88, Tirap, TRIF, TRAF6, IFNβ, pIRF3 and NF-kB] |
| Oliveira et al. [63] | α-linolenic (ω3) or oleic (ω9) fatty acids - 10% chow | 8 weeks | Swiss Mice              | [IL-1β, IL-6 and TNFα] | [IL-10) | GPR120 |
| Ye et al. [64]       | Berberine—50 mg/kg/day     | 14 days | C57BL/6j mice           | × Macrophage polarization M1 | MCP-1, IL-6 and TNF-α | [IL-10, JP-1, IKKβ and Akt] | NF-kB | F4/80, CD206 | CD11c |

(Continued)
Table 2. (Continued)

| Author | Compound/Dose and frequency | Time | Animals/Species | Outcomes |
|--------|-----------------------------|------|----------------|----------|
| Gao et al. [65] | Rutin—50 mg/kg twice a week | 8 weeks | C57BL/6j mice | Arteriopathy and CLS | TNF-α, MCP-1, CD68, CD206 and Arg1 |
| Kang et al. [66] | Capsaicin—0.015% chow | 10 weeks | C57BL/6j mice | Adiponectin | MCP-1, TNFα, IL-6, leptin |
| Veeramani et al. [67] | Lavatera critica (LC) - 50, 100 or 200 mg/kg/day | 5 weeks | C57BL/6j mice | Adiponectin | TNF-α, IL-1β, IL-6, MCP-1 and CD11c |
| Yang et al. [68] | Bitter melon—1 or 3% chow | 6 weeks | OLETF rats | Adiponectin | TNF-α and IL-6 | CCL2, TNF-α |
| Ying et al. [69] | Interferon tau—8 μg/kg/day | 8 weeks | C57BL/6j mice | Adiponectin | TNF-α and IL-6, α and TNF-α and macrophage |
| Zhou et al. [70] | Catalpol—100 mg/kg/day | 4 weeks | C57BL/6j mice | Adiponectin | TNF-α, IL-1β, IL-6, MCP-1, and CD11c |
| Subramanian et al. [71] | Terminalia chebula Fruit Extract— 50 mg/kg/day | 9 weeks | C57BL/6j mice | Adiponectin | TNF-α, IL-6, PPARα, CPT-1α, FAS, adiponectin |
| Yu et al. [72] | Sarsasapogenin— 40 or 80 mg/kg/day | 6 weeks | C57BL/6j mice | Adiponectin | IL-1β, IL-2, TNF-α and IFN-γ |
| Bashir et al. [73] | Fish oil—4, 8 or 16 mg/kg | 4 weeks | C57BL/6j mice | Adiponectin | IL-1β, IL-2, TNF-α and IFN-γ | NF-kB, TLR4 |
| Bettie et al. [74] | Flavan-3-ol (−)epicatechin—20 mg/kg/day | 15 weeks | C57BL/6j mice | Adiponectin | TNF-α, MCP-1 and F4/80 |
| Guo et al. [75] | Cianidin-3-glucoside—0.2% chow | 5 weeks | C57BL/6j, C57BL/Ks db/db and db/+ mice | Adiponectin | TNF-α and IL-6, F4/80, CD11c and MCP-1 |
| Kwon et al. [76] | Coptidis Rhizoma— 200 or 400 mg/kg/day | 10 weeks | C57BL/6j mice | Adiponectin | α, IL-β, IL-6, MCP-1, CD68, CD206, CD86 |
| Lee et al. [77] | Broussonetia papyrifera root bark extract—40 mg/kg/day | 7 days | C57BL/6j mice | Adiponectin | NF-kB, IL-1β, IL-6, INF-α, MCP-1 |
| Pericatico et al. [78] | Quercetin—20 mg/kg/day | 6 weeks | Sprague Dawley rats | Adiponectin | NF-kB, IL-1β, IL-6, INF-α, MCP-1 and M2 |
| Ramalho et al. [79] | Eicosapentaenoic Acid— 36 g/kg chow | 11 weeks | C57BL/6j mice | Adiponectin | Allo5, Myd88, Stat1, Ccr5, Card11 and LTB4 |

**Synthetics**

| Author | Compound/Dose and frequency | Time | Animals/Species | Outcomes |
|--------|-----------------------------|------|----------------|----------|
| Dinh et al. [80] | Bardoxolone methyl (BARD) - 10 mg/kg/day | 21 weeks | C57BL/6j mice | Adiponectin and CCL |
| Wang et al. [81] | Sodium bururate—1 g/kg every two days | 6 weeks | C57BL/6j and C57BL/6j db/+ mice | Adiponectin and CCL |
| Bak et al. [82] | Licorichalcones—10 mg/kg/day | 3 weeks | C57BL/6j mice | Adiponectin and CCL |
| Gambaro et al. [83] | Specin—29 μg/kg/dia | 10 days | Swiss Mouse | Adiponectin and CCL |
| Chen et al. [84] | Sea cucumber saponin liposomes—0.45 mg/mL | 8 weeks | C57BL/6j mice | Adiponectin and CCL |

† Increase † Decrease × Inhibit ⊕ Stimulate © Phosphorylation

COX2: cyclooxygenase enzyme. TNF-α: tumor necrosis factor alpha. PPAR-γ2: peroxisome proliferator-activated gamma receptors. CEBP-α: CCAAT-enhancer-binding proteins. SREBPc: sterol regulatory element binding proteins. TLR2/4: toll-like receptors. MyD88: myeloid differentiation primary response gene 88. JNK: c-Jun N-terminal kinases. iNOS: inducible nitric oxide synthase. MGL-1: macrophage galactose-type lectin 1. NOX4: NADPH oxidase 4. FoxO1: Forkhead Box O1. ST3: signal transducer and activator of transcription 3. NLRP-3: NLR family pyrin domain containing 3. FAS: Fas cell surface death receptor. INF-α/β: interferons. IL-1, IL-6, IL-10, IL-13: interleukins. MCP-1: monocyte chemoattractant protein-1. NF-kB: nuclear factor kappa B. CLS: crown-like structures. LPL: lipoprotein lipase. IRS-1: insulin receptor substrate 1. GLUT-4: glucose transporter. LXB4: lipoxin A4. ARG-1: arginase 1. AMPK: AMP-activated protein kinase. UCP-1/2/3: uncoupling protein. SGLT2: sodium/glucoe cotransporter 2

https://doi.org/10.1371/journal.pone.0273942.1002
Mechanisms of action of anti-inflammatory agents in the adipose tissue

In the collected data, most anti-inflammatory agents generated outcomes that favored the reduction of pro-inflammatory markers expression by decreasing the infiltration of macrophages in white adipose tissue (WAT) and polarization of M1-type macrophages to M2.

Therefore, because obesity is a disease of multifactorial origin associated with inflammation, the treatment of obesity becomes a challenge. In many cases, lifestyle changes do not present themselves as lasting tools for weight loss. Thus, drug therapy, such as anti-inflammatory agents that complement the caloric deficit and the practice of physical activity, might be used [85].

Considering the class of drugs, Hsieh et al. [45] evaluated the effect of a selective COX-2 inhibitor (celecoxib or mesulid) on inflammation. The study demonstrated that the inhibition of the COX-2 gene significantly reversed adipocyte hypertrophy, macrophage infiltration, and the genetic expressions of TNF-α, PPAR-γ, and CCAAT-enhancer-binding proteins (C/EBP-α) in epididymal adipose tissue. In contrast, Carvalho et al. [86] evaluated the effect of treatment with a purified tamarind trypsin inhibitor (TTIp) on metabolic changes in obesity. The results showed that the treatment reduced the expression of the TNF-α gene and protein, with no relative effects on the PPAR-γ mRNA expression, which indicates that the reduction occurred in a PPAR-γ independent pathway.

Ma et al. [46] used the drug Dextran (D-70) and observed that receptor-mediated M1 macrophages endocytose the Dextran conjugates (D-rad and D-PEG-rad), and free dexamethasone is released into cells. Dexamethasone then binds to the glucocorticoid receptor, inhibiting the transcription of pro-inflammatory genes, decreasing adipocyte hypertrophy, and consequently reducing the production of MCP-1. This protein is responsible for recruiting monocytes and releasing cytokines and chemokines locally through the NF-κB activation. Thus, it reduces the MCP-1 production, decreases inflammation in the adipocyte, decreases TNF-α, IL-6, and MCP-1, size of adipocytes, and crown-like structures (CLS), suggesting a reduction in infiltrated macrophages.

Ndisang & Jadhav [47] observed that the administration of the drug Hemin induced an increase in the release of adiponectin and the activation of AMPK, which stimulates the translocation of GLUT-4, being associated with increased protein expression of IRS-1, PKB/AKT. These factors caused a decrease in oxidative/pro-inflammatory transcription factors NF-κB, AP-1, and JNK, reducing TNF-α, IL-6, and IL-1β, MCP-1, and ICAM-1 in the adipose tissue.

Furuya et al. [12] demonstrated that atorvastatin suppressed both IKK-β and IKK-α phosphorylation, decreasing the expression of NF-κB target genes such as TNF-α and IL-6. Increased GLUT-4 gene and protein expression were also observed.

Okada et al. [48] evaluated the pioglitazone’s action, a thiazolidinedione (TZD) in KKAY mice. The results showed that pioglitazone regulated the production of lipoxin B4 (LXB4), a lipid mediator, in adipocytes, decreased Prostaglandin 2, and induced the mRNA expression of IL-10, IL-13, and Arg-1, concluding that this mediator may have an anti-inflammatory effect on adipose tissue. Xu et al. [49] used Empagliflozin, also of the TZD class, and SGLT2 inhibitor. The drug acted by inhibiting SGLT2 and activating the AMPK pathway, consequently increasing the mRNA expression of adiponectin and UCP-1. Thus, reducing CLS and pro-inflammatory gene factors such as leptin and F4/80 were also observed.

Prabhu et al. [50] evaluated the action of dextran-based dexamethasone (ND) conjugates in an obesity model. It was observed that ND promoted the marked regulation of inflammation markers and lymphocyte infiltration (TNFa, CD68, CD11c, CD8a, CCR5, CD64, F4/80, CCL3), as well as reduced expression of metabolic markers (ACACA, UCP3, PCK1, and IRS2). A reduction in pro-inflammatory macrophage markers (IL-6, FASL, CCR5, CCL2, NOS2, IFNG,
FCGR1) and inflammation markers (TNFα, IL-6, IL-1β, CCR5, CCR2, CCL2, FCGR1, NOS2), while the macrophage marker M2 (CD206) increased substantially with ND treatment. Together, these results point to a change in the phenotype of macrophages from M1 to M2 more expressively for ND.

Zhou et al. [51] analyzed a peptide-1 (GLP-1) (Ex-4) 2-Fc analog in anti-inflammatory functions in adipose tissue. The treatment reduced the expression of IL-1β, TNF-α, IL-6, and MCP-1, in addition to the mRNA levels of the cytokines IL-4 and IL-13. M1 macrophage reduction and M2 macrophage increase were also observed. Besides, the expression of their relative markers CD11b, F4/80, iNOS, and an increase in CD206. When evaluating the inflammatory signaling pathways in adipose tissue, the data showed that the treatment affected the gene expression of the AMPK pathway, reducing the phosphorylation of NF-κB and p38, in addition to the expression and secretion of leptin. These results suggest that (Ex-4)2-Fc suppresses inflammatory signaling pathways, inhibiting NF-κB, p38, and AMPK phosphorylation due to reduced leptin levels in adipose tissue.

Considering natural agents, Lee et al. [52] evaluated the effects of treatment with Metabolaid® (MetA), a combination of lemon verbena and hibiscus flower extracts, on obesity. The treatment decreased the genes related to adipogenesis, CEBP/α, PPARγ, and SREBP-1c in AT. The results also showed an increase in the mRNA expression of the UCP1 and UCP2, which can contribute to the darkening of WAT, promoting thermogenesis, thereby increasing energy expenditure. Besides, the treatment reduced the pro-inflammatory cytokines TNF-α and IL-6. Also, an increase in the phosphorylation of AMPK was observed, indicating that the activation of AMPK may be responsible for reducing adiposity.

Fenni et al. [53] evaluated the supplementation of lycopene and tomato powder in inflammation induced by obesity. Supplementation reduced adipocyte hypertrophy and PPAR-γ gene expression, which is considered a key regulator in adipogenesis, thus explaining the reduction in adiposity in supplemented mice. A reduction in the transcription factor SREBP-1c and the FAS gene was also observed. The results also showed a decrease in gene pro-inflammatory cytokines (TNF-α, IL-6) and chemokines (CCL2 and CCL5), which are explained by reducing phosphorylation of p65 and IκB, two important factors of NF-kB signaling. The results suggested that these compounds’ anti-inflammatory effect on adipose tissue results from their ability to inhibit NF-κB signaling in adipose tissue.

Abu Bakar et al. [54] investigated the metabolic effects of Celastrol on the inflammatory response in adipose tissue. When evaluating the mRNA expression of pro-inflammatory genes, it was found that the treatment repressed the expression of IL-6, TNF-α, and MCP-1 in adipose tissue. Besides reducing the phosphorylated activity of NF-κB, mRNA expressions of iNOS and CD11c restored the level of Arg1. These results indicate that the improvement in the inflammatory state promoted by Celastrol is associated with a reduction in NF-κB phosphorylation and the polarization of M1-type macrophages in adipose tissue.

Alsaggar et al. [55] in their study aimed to evaluate the anti-inflammatory and antioxidant effects of Silibinin in an obesity model. The treatment suppressed fat accumulation and adipocyte hypertrophy and reversed the pro-inflammatory to anti-inflammatory gene expression profile. The researchers verified the reducing F4/80 and CD11c expression, suggesting a reduction in the infiltration of the immune cells in the AT, in inflammatory cytokines TNF-α and IL-6 expression, and regulation of the IL-10 and adiponectin expression. These data indicate that silibinin acts by blocking inflammation in adipose tissue, which can be explained by the inhibitory effects of silibinin on NF-κB.

Han et al. [56] aimed to explore the underlying effects of Berberine on obesity-induced inflammation. The results showed that Berberine reduced the mRNA expression of IL-6 and MCP-1 and prevented the increased expression of F4/80 and TNF-α. The treatment also
increased IL-4, CD206, and ARG1, M2 macrophage markers. Flow cytometry data also indicated blockade of macrophage infiltration into adipose tissue and an increase in the M1 to M2 macrophage ratio. Furthermore, Berberine restored CD163 expression and decreased CD68 expression, indicating suppression of macrophage infiltration and promotion of M2 polarization.

Choi et al. [57] investigated the effect of Indole-3-carbinol, a natural compound found in brassica, on adipose tissue inflammation. Supplementation increased the mRNA expression of Sirtuin 1 (SIRT1) and Coactivator 1a (PGC1a), leading to the expression of the UCP1 and UCP3 genes, which are essential factors in thermogenesis. The results demonstrate that the possible mechanism of attenuation of the inflammation was suppressing the pro-inflammatory cascades mediated by Toll-2 and 4 type receptors (TLRs, toll-like receptors), considering the phosphorylation levels of these pathways were reduced in adipose tissue. When stimulated, these pathways recruit adapter molecules, such as myeloid differentiation primary response gene 88 (MyD88). In the study, these levels, together with their target cytokines (TNFα, IFNβ, and IL-6) genes, were reduced, confirming the decrease in inflammation dependent on these pathways.

Ma et al. [58] evaluated the anti-obesity impact of spermidine. The results showed that the treatment reduced the size of adipocytes and the number of CLS. Decreased infiltration of F4/80 macrophages and attenuation of phosphorylation of p38 AMPK and p65 NF-kB were also observed. Furthermore, the treatment reduced the mRNA expression of SREBF1c, FAS, and PPARγ in the same way that it reduced the expression of IL-1β, IL-6, iNOS, MCP-1, CCL5, and leptin. It was observed that the reduction of the inflammatory profile might have been regulated through the inactivation of NF-kB and AMPK, which has been reported as a regulatory kinase of NF-kB.

Wei et al. [59] investigated docosahexaenoic acid (DHA, 22:6) and eicosapentaenoic acid (EPA, 20:5) in the treatment of obesity in mice, using doses ranging from 1 to 4% (w/w). The results showed a reduction in the size and number of adipocytes, attenuating the inflammatory infiltration in the adipose tissue due to the decrease in IL-6, TNF-α, CD11c, and the increase in the expression of CD206, a marker of macrophage M2. FAS and ACC reduced expression, an increase in adiponectin, and an inhibition of the increase in leptin were also observed. The treatment also showed that EPA 2% might have a regulatory role of GPR120, and EPA 1% and DHA 4% may have regulatory roles in inflammation through PPARγ, independent of GPR120, stimulating the dimming of WAT. In contrast, 1% DHA and 4% EPA exerted regulatory effects by mechanisms independent of GPR120 and PPARγ.

Cho et al. [60] evaluated the effects of treatment with Carvacrol. The results showed that the treatment reduced the expression of pro-inflammatory cytokine genes (TNFα and IFNα), leptin, and the mRNA and protein of TLR-2, TLR-4 levels, and their molecules (MyD88, Tirap, TRIF, TRAF6, IRF5, and IRF3). TLR-2 uses the MyD88-dependent pathway, using TRAF-6 and IRF5, leading to NF-κB translocation and cooperation. TLR-4, on the other hand, uses TRIF to activate NF-κB in a mechanism dependent or independent of TRAF-6, leading to phosphorylation of IRF3. The reduced mRNA and protein levels in the treated adipose tissues explain the decrease of pro-inflammatory cytokines. It suggests that meta-inflammation was reduced by inhibiting the TLR-2 and TLR-4 pathways.

Lee et al. [61] observed that treatment with black raspberry oil reduced mRNA and protein expression of TLR-4 and NF-κB and the levels of mRNA of pro-inflammatory cytokines (TNFα and IL-6) and macrophage markers (F4/80, CD68, MCP-1). Furthermore, there was an increase in mRNA levels of anti-inflammatory markers IL-10, Arg1, and macrophage galactose-type lectin 1 (MGL1) in adipose tissue. Thus, this compound’s possible mechanism of action is by inhibiting TLR-4.
Kim et al. [62] evaluated the effects of resveratrol. The results showed a decrease in mRNA levels of several adipogenic transcription factors, including PPARγ2, C/EBPa, and SREBP-1c, while the reduction of ERK phosphorylation was also observed through protein analysis. The mRNA TLR-2 and TLR-4 levels were reduced, as well as the MyD88, TIRAP, TRAF-6, and TRIF genes expression as the pro-inflammatory transcription factors IRF3, IRF5, and NF-κB. These findings, as previously mentioned, justify the reduction of the gene expression of the pro-inflammatory cytokines TNFα, IFNα, INFβ, and IL-6, by blocking the pro-inflammatory signaling cascades mediated by TLR-2 and TLR-4.

Oliveira et al. [63] tested the effects of diets containing α-linolenic (ω3) or oleic (ω9) fatty acids. The treatments reduced the expression of the pro-inflammatory markers IL-1β, p-IKK, p-IκBα, TNFα, and p-JNK, and mRNA expression IL-6, and the increased expression of IL-10 mRNA. Activation of the G protein-co coupled receptor (GRP120) was also reported. This activation results in the recruitment of β-arrestin and, consequently, in the impairment of inflammatory signaling through TAB1/2, an important transduction pathway for receptors such as TRL-4, thus inhibiting its inflammatory signal. This mechanism explains the reduction in the pro-inflammatory markers’ expression, which is an important way of suppressing inflammation using fatty acids.

Ye et al. [64] evaluated the treatment with Berberine, which inhibited the MCP-1, IL-6, and TNF-α mRNA expressions in adipose tissue, inhibited the phosphorylated activation of JNK, IKKβ, AKT, and reduced the expression of the p65 subunit NF-xB. The M1 macrophage cells (F4/80, CD206) reduction and the M2 (CD11c) increase were demonstrated, demonstrating that the treatment decreased the accumulation of M1 macrophages and the high ratio of M1 and M2 macrophages in adipose tissue. In this way, the treatment inhibits the polarization and activation of M1 macrophages and, consequently, the inflammatory state.

Gao et al. [65], using rutin, observed decreased adipocyte hypertrophy and CLS. As well as reduced mRNA levels of TNF-α and MCP-1, and reduced gene expression F4/80, CD11c, and CD66b, which are markers of pro-inflammatory macrophages and activation markers of pro-inflammatory macrophages and gene activation of CD206 and Arg-1. Rutin suppressed the process of infiltration and aggregation of macrophages around necrotic adipocytes, reducing the development of CLS and chronic inflammation, suggesting the anti-obesity effect of this antioxidant. The increase in Arg-1 is associated with a higher proportion of M2 macrophages, characterized as an anti-inflammatory.

Kang et al. [66] evaluated the treatment with capsaicin, which caused a reduction in the genetic and protein expression of MCP-1, TNFα, IL-6, and leptin, and increased the mRNA expression of adiponectin. Besides, the mRNA expression of the potential transient vanilloid type-1 receptor (TRPV-1), a specific receptor for capsaicin, was evaluated. An increase in TRPV-1 mRNA expression in adipose tissue has been demonstrated, indicating that TRPV-1 is involved in the inhibitory effect of dietary capsaicin on obesity-induced adipose tissue inflammation.

Veerami et al. [67] used Lavatera critica (LC), a green herb used in folk medicine. The treatment reduced pro-inflammatory genes TNF-α, IL-1β, IL-6, iNOS, MCP-1, and CD11c. In contrast, the expression of the anti-inflammatory genes Ym-1, ARG1, and Clec7a was increased. The attenuation of enzymatic (SOD and GPx) and non-enzymatic (total proportion of GSH and GSH/GSSG) attenuation was also observed. Thus, the compound acts by reducing inflammation and damage from oxidative stress.

Yang et al. [68] evaluated the effects of bitter melon (Momordica charantia), which reduced the mRNA expression of TNF-α, IL-6, and CCL2 in adipose tissue and reduced phosphorylation of NF-κB (p65) and JNK. These pathways are possibly the main ones responsible for suppressing the inflammation used by this compound.
Ying et al. [69] used Interferon tau to treat inflammation in obesity. The treatment suppressed the activation of NF-κB, thus evidenced by the lower p65 phosphorylation and activity of the JNK pathway, evidenced by the decrease in p-JNK. The IL-1β, IL-6, and TNF-α genes' expression were also reduced, and there was an increase in the anti-inflammatory cytokine IL-10 gene expression. It was also observed that the number of pro-inflammatory M1 macrophages was drastically reduced, in contrast to the significant increase in M2 macrophages, suggesting regulation in the polarization of macrophages.

Similarly, Zhou et al. [70] using Catapol, a bioactive compound found at the root of glutinous Rehmannia, observed pro-inflammatory M1 gene expression, such as TNF-α, IL-6, IL-1β, MCP-1, iNOS, and CD11c had been reduced. The expression levels of M2 anti-inflammatory genes, such as ARG1, Ym-1, IL-10, MGL1, and Clec7a, were significantly increased. There was also a reduction in CLS and F4/80, proving the decrease in macrophage infiltration. These results indicate that the catapol can redirect M1 macrophages to an M2 polarized state, explaining the inflammatory state's reduction. A significant decrease in the JNK and IKKβ phosphorylation was also mentioned, minimizing the activation of NF-κB p50, indicating that treatment through these pathways contributes to the AT’s protective effect against inflammation.

Subramanian et al. [71] evaluated the anti-obesity effects of Terminalia chebula fruit extract. It was observed that the treatment regulated the protein levels and gene expression of FAS, PPARα, and CPT-1α, reducing TNF-α and IL-6 cytokines, decreasing adiponectin levels, and increasing leptin levels. These results indicate the protective role of the extract in the development of inflammatory responses. These effects are related to the suppression of lipogenesis by reducing FAS and the increase in the oxidation of fatty acids by PPARα and CPT-1α activity, culminating in the anti-inflammatory responses.

Yu et al. [72] investigated the effects of sarsasapogenin (ZGY) on adipose tissue inflammation. The results showed that the treatment suppressed the expression of the pro-inflammatory genes TNF-α, IL-1β, IL-6, MCP-1, Nos2, COX2, and adiponectin, and a simultaneous increase in Arg1, Ym1,Fizz1, and IL-10. Inactivation of inflammatory signaling pathways IKK, NF-κB, and JNK was also observed and increased IκB-α protein level in adipose tissue. The treatment reduced the percentage of F4/80 cells, the expression of F4/80 and CD68, M1 markers, and increased the levels of genes associated with M2 IL-10, Ym1, and Fizz1. These results indicate that the mechanism of action attenuating inflammation occurs through the inactivation of the IKK, NF-κB, and JNK signaling pathways.

Bashir et al. [73] evaluated the effects of fish oil on inflammation. A decrease in NF-κB/p65 levels was observed, as well as pro-inflammatory cytokines (TNF-α, IFN-γ, IL-1β, and IL-2) expression and an anti-inflammatory increase (IL-4 and IL-10). The cytometric analysis demonstrated a decrease in TLR-4, which may be responsible for decreasing the inflammatory state. Besides, an increase in ARGI mRNA was observed, suggesting a greater polarization of M2 macrophages.

Bettaieb et al. [74] using flavan-3-ol (−)—epicatechin (CE) showed that the treatment decreased the F4/80 protein and reduced the phosphorylation of IKK, IκB, and p65, inhibiting the NF-κB signaling pathway. Besides, a reduction in TNF-α and MCP-1 was seen, and a decrease in protein expression of NADPH Oxidase 4 (NOX4) and p47 means oxidative stress attenuation. Thus, inhibition of the NOX4 pathway led to attenuation of JNK and IKK/NF-κB, justifying the reduction of pro-inflammatory cytokines and the recruitment of M1 macrophages.

Guo et al. [75] evaluating the effects of anthocyanin cyanidin 3-glucoside, noticed a reduction in the macrophage markers F4/80 (Emr1) and Cdl1c and a lower infiltration of macrophages in TA. There was also a decrease in mRNA expressions of TNF-α, IL-6, and MCP-1 and
the activation of JNK and Forkhead Box O1 (FoxO1). Thus, it was suggested that anthocyanins blocked the activation of JNK/FoxO1, suppressing the expression of pro-inflammatory cytokines and improving the inflammatory condition.

Kwon et al. [76] evaluated the mechanisms and effects of *Coptidis rhizoma* on obesity-induced inflammation. The results showed that the treatment reduced the percentage of M1 CD11c macrophages and increased the M2 CD206 macrophages. A reduction in the expression of TNF-α, F4/80, CCL2, CCL4, and CCL5 was also observed. These results indicate that Coptidis Rhizoma reduces chronic low-grade inflammation by reducing macrophage infiltration and shifting from M1 to M2 macrophage phenotype.

Lee et al. [77] evaluated the effects of *Broussonetia papyrifera* root bark extract in treating inflammation associated with adipose tissue. After treatment, the results showed a decrease in NF-κB phosphorylation and an increase in AMPK phosphorylation in WAT, and a reduction in the expression of pro-inflammatory genes IL-1β and iNOS. These findings indicated that the treatment inhibited the inflammatory responses induced by TNF-α by suppressing the activation of NF-κB, proposing that this extract acted by inhibiting this pathway by blocking the degradation of IkB.

Perdicaro et al. [78] used quercetin in the treatment of adipocyte hypertrophy and inflammation. The results indicated that supplementation reduced the size of adipocytes and modified the levels of proteins involved in angiogenesis and adipogenesis, reducing HIF-1α and increasing VEGF-A and VEGF-R2. An increase in the regulation of protein levels of PPARγ, C/EBPα, adiponectin, and FAS was also observed, indicating the activation of adipogenesis. Supplementation also reduced the protein expression of TLR4, CD68, MCP-1, and p-JNK, indicating a reduction in macrophage infiltration in adipose tissue. These results suggest that quercetin can stimulate a healthy expansion in WAT, promoting angiogenesis and adipogenesis.

Ramalho et al. [79] evaluated eicosapentaenoic acid (EPA) in regulating metabolic and inflammatory pathways through the modulation of transcripts and miRNA in TAB. The results showed a lower expression of adipocyte hypertrophy and inflammation, such as *Arachidonate 5-lipoxygenase* (Alox5), *Myd88*, *Stat1*, *Ccr5*, and *Cnd11* lower production of LTB4, consistent with the reduction of Alox5. These data suggest that EPA can downregulate inflammatory pathways. However, it negatively affects the LTB4 synthesis machinery, as EPA and other free fatty acids (FFA) are regulated by EPA supplementation in hypertrophic adipose tissue. When analyzing the effects on the microRNAs involved in inflammation, it was observed that EPA reduced the expression of miR-146b and miR-125b-5p, indicating that this reduction would probably be through the decrease of TLB4. It was also found that the regulation of miR-30a-5p and miR-143-3p indirectly decreases inflammatory targets, such as c-jun and c-fos (part of the MAPK signaling pathway).

Regarding synthetic materials, Dinh et al. [80] evaluated Methyl Bardoxolone in the treatment of obesity. Decreased F4/80, protein expression of TNF-α, and protein levels of molecules activated by oxidative stress (STAT3, Akt, ERK, and JNK) have been reported. Thus, the authors discussed that this compound has an antioxidant effect, responsible for reducing obesity and the pro-inflammatory state.

Wang et al. [81] used sodium butyrate to treat inflammation in adipose tissue, and this compound reduced the CD68, INF-γ, and MCP-1 mRNA, the number of F4/80 cells, and the IL-1, IL-6 gene expression, and TNF-α. The treatment also inhibited the expression of NLRP3 and caspase-1 mRNA. Thus, one of the possible mechanisms by which the suppression of inflammation occurs is the inhibition of this pathway.

Bak et al. [82] evaluated the Licorhcalone F1’s action, observed a reduction in the adipocytes’ size and the infiltration of macrophages. The results also showed decreased CD68,
TNFα, and MCP-1 expression genes, increased Akt phosphorylation and reduced p38 phosphorylation. Therefore, the modification in the adipocytes’ structure may have been responsible for reducing pro-inflammatory cytokines. Besides, MAPK proteins, such as p38, have an essential role in regulating these cytokines. The phosphorylation of p38 MAPK in adipose tissue indicates an inhibitory effect on p38 MAPK, possibly leading to anti-inflammatory responses.

Gambaro et al. [83] evaluated the role of spexin as a modulator of the immune response of adipose tissue in obesity. The treatment reduced adipocyte size, restored leptin expression levels, reduced TNF-α, IL6, and IL-1β levels, and increased CD206 levels. Besides, CD11b, Ly6C, and M1 CD11c monocytes were reduced. When comparing macrophage populations, it was found that M2 Ly6C macrophages were more abundant after treatment, demonstrating the modulation of inflammation in WAT, improving the M1/M2 ratio.

Chen et al. [84] used a treatment with marine cucumber saponin liposomes. The treatment reduced the mRNA expressions of pro-inflammatory cytokines TNF-α and IL-6 and decreased macrophage infiltration in the adipose tissue, which decreased the F4/80 and CD11b mRNA expression. Increases in prostaglandin and ERK phosphorylation inhibition have also been observed, probably one of the leading causes of reduced pro-inflammatory markers.

Additionally, it was observed that the studies included in this review also emphasized, as possible explanations for the improvement in the inflammatory profile, the action of anti-inflammatory agents on adipocyte hypertrophy/hyperplasia, as well as on the beige of adipose tissue. Therefore, studies have highlighted these factors as responsible for thermogenesis and weight and body fat changes.

In some studies, the authors reported that the browning of white adipose tissue occurred, which increased thermogenesis, energy expenditure, and weight reduction. Besides, reducing M1-type macrophages and increasing M2-type macrophages in fat and liver impact reduced insulin resistance and reduced inflammation, especially in adipose and liver tissue [50, 51, 52, 56–59, 64–66, 69, 70, 72, 75, 76, 83].

Based on this, considering the various regulatory functions of adipose tissue, and according to the studies mentioned above, the expansion of this tissue stands out for its impact on adipose cell inflammation, as well as on body energy balance and glucose homeostasis. Such dysfunctions are associated with the risk of several chronic diseases, causing systemic effects that include increased body weight, insulin sensitivity, and metabolic disorders that impact the body in general. Thus, this review presented the anti-inflammatory agents that act directly on adipose tissue in preclinical analyses, can serve as a basis to guide clinical studies, and, in the future, these agents will be used in more comprehensive treatments that aim at targets related to regulatory functions of the AT.

However, suppression of adipocyte inflammation can result in adipose tissue dysfunction and promote insulin resistance. Zhu et al. [87] evaluated the relative contributions related to inflammation of adipocytes and macrophages to insulin sensitivity. The results showed that, even with the reduction of adipocytes, body weight, and suppression of inflammatory pathways (TNFα and IL-1β), glucose tolerance was intensified, increasing insulin resistance, fatty liver, and reducing adiponectin. This suggests that despite the beneficial effects on weight gain, suppression of adipocyte inflammation impaired adipose tissue function and promoted insulin resistance.

Asterholm et al. [88] evidenced that pro-inflammatory signaling in adipocytes was essential for good remodeling and expansion in adipose tissue. The researchers used mice with a specific reduction in the pro-inflammatory potential in adipose tissue, which, when exposed to a high-fat diet, had tissue expansion prominently affected. These effects were related to decreased intestinal barrier, increased hepatic steatosis, and metabolic dysfunction and led to
increased accumulation of ectopic lipids, glucose intolerance, and systemic inflammation. In conclusion, inflammatory signaling in adipocytes is an adaptive response that allows the safe storage of nutrients and contributes to a visceral deposition barrier that filters gut-derived endotoxins.

Thus, even though the present review shows and gathering anti-inflammatory agents that acted directly on adipose tissue in preclinical studies with numerous positive effects, it is still necessary to evaluate in a broad and detailed way. However, this information can serve as a basis to guide clinical studies. In the future, these agents will be used in more comprehensive treatments that target related to regulatory functions of the AT, without causing harm, for example, insulin intolerance or resistance. It also highlights the importance of future studies in women (feminine gender), whether preclinical or clinical, to investigate how these anti-inflammatory agents act on the adipose tissue of this gender.

Finally, the studies included in this systematic review made it possible to infer that a large part of the bioactive compounds, drugs, and synthetic compounds act in metabolic pathways that culminate, mainly in reducing the expression of inflammatory cytokines. This action favors a reduction in macrophages' infiltration in white adipose tissue and causes a polarization process of macrophages of type M1 to M2 (Fig 3).

The mechanisms highlighted in this review were proposed only considering studies conducted with male animals. It is known that male mice have greater weight gain than females and, therefore, are ideal for comparison focusing on white adipose tissue. In addition, several hormonal factors can regulate inflammatory pathways in females and promote differences in metabolic reproduction [89–93]. Therefore, studies involving the female animals were excluded, thus following the exclusive determination activity, since the study’s primary objective covers the specific antiadipogenic mechanisms.

The limitations of this review are related to not performing a meta-analysis, considering the clinical, methodological, and statistical heterogeneity of the results and the variability of the articles included. It is also important to highlight the methodological quality of the articles, as many studies do not present items at risk of bias, leaving the evaluation less clarified. However, the results portray scientific evidence of high relevance concerning the topic addressed.

**Conclusions**

Several anti-inflammatory agents have been evaluated for mechanisms of action to suppress inflammation in adipose tissue. We can observe that drugs, natural and synthetic compounds act in several ways that meet and unite to suppress inflammation. Among the primary outcomes found a reduction in anti-inflammatory cytokines, adipocyte hypertrophy, which ultimately cause a decrease in macrophage infiltration, and a change in the polarization of M1→M2 macrophages, inducing an anti-inflammatory state and suppression of inflammation in the AT.

Therefore, using these anti-inflammatory agents is relevant to developing new studies and clinical trials aiming at promising new treatments for obesity and metabolic changes resulting from this state of inflammation. Furthermore, it is noteworthy that in two studies presented in this review, suppression of adipocyte inflammation resulted in adipose tissue dysfunction and promoted insulin resistance.

This systematic review synthesizes and schematizes presenting various molecules targeted by anti-inflammatory agents through mechanisms that increase or decrease their expressions at the molecular, systemic, or tissue level. This evidence may improve and choose the anti-inflammatory agent for possible applications aiming at future treatments with specific and promising targets.
Fig 3. Mechanisms of action of anti-inflammatory agents in adipose tissue on the expression of genes and proteins in a hypothetical cell. Anti-inflammatory agents (Drugs, natural and synthetic compounds) act in several ways that cross and culminate in reducing infiltration of immune cells, reducing the pro-inflammatory profile, and changing the M2 and M1 polarization, inducing an anti-inflammatory profile and suppressing inflammation in obesity. COX2: cyclooxygenase enzyme. TNF-α: tumor necrosis factor-alpha. PPAR-γ: peroxisome proliferator-activated gamma receptors. CEBP-α: CCAAT-enhancer-binding proteins. SREBPc: sterol regulatory element-binding proteins. TLR2/4: toll-like receptors. MyD88: myeloid differentiation primary response gene 88. JNK: c-Jun N-terminal kinases. iNOS: induced nitric oxide synthase. MGL-1: macrophage galactose-type lectin 1. NOX4: NADPH oxidase 4. FoxO1: Forkhead Box O1. STAT3: Signal transducer and activator of transcription 3. NLRP-3: NLR family pyrin domain containing 3. FAS: Fas cell surface death receptor. INFα/β: interferons. IL-1, IL-6, IL-10, IL-13: interleukins. MCP-1: monocyte chemoattractant protein-1. NF-kβ: nuclear factor-kappa β. CLS: crown-like structures. LPL: lipoprotein lipase. IRS-1: insulin receptor substrate 1. GLUT-4: glucose transporter. LXB4: lipoxin A4. ARG-1: arginase 1. AMPK: AMP-activated protein kinase. UCP-1/2/3: uncoupling protein. SGLT2: sodium/glucose cotransporter 2.

https://doi.org/10.1371/journal.pone.0273942.g003

Supporting information

S1 Checklist. PRISMA 2020 checklist. (DOCX)

Author Contributions

Conceptualization: Thaís Souza Passos, Ana Heloneida de Araújo Morais.

Data curation: Sara Sayonara da Cruz Nascimento, Grasiela Piuvezam, Thaís Souza Passos, Ana Heloneida de Araújo Morais.
Formal analysis: Sara Sayonara da Cruz Nascimento, Grasiela Piuvezam, Bruna Leal Lima Maciel, Thaís Souza Passos, Ana Heloneida de Araújo Morais.

Funding acquisition: Thaís Souza Passos.

Investigation: Sara Sayonara da Cruz Nascimento, Jaluza Luana Carvalho de Queiroz, Amanda Fernandes de Medeiros, Ana Clara de França Nunes.

Methodology: Sara Sayonara da Cruz Nascimento, Grasiela Piuvezam, Thaís Souza Passos, Ana Heloneida de Araújo Morais.

Project administration: Thaís Souza Passos, Ana Heloneida de Araújo Morais.

Supervision: Grasiela Piuvezam, Thaís Souza Passos, Ana Heloneida de Araújo Morais.

Validation: Sara Sayonara da Cruz Nascimento, Thaís Souza Passos.

Writing – original draft: Sara Sayonara da Cruz Nascimento, Grasiela Piuvezam, Bruna Leal Lima Maciel, Thaís Souza Passos, Ana Heloneida de Araújo Morais.

Writing – review & editing: Sara Sayonara da Cruz Nascimento, Jaluza Luana Carvalho de Queiroz, Amanda Fernandes de Medeiros, Ana Clara de França Nunes, Grasiela Piuvezam, Bruna Leal Lima Maciel, Thaís Souza Passos, Ana Heloneida de Araújo Morais.

References
1. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. Springer International Publishing; 2015. pp. 673–689. https://doi.org/10.1007/s40273-014-0243-x
2. World Health Organization. Obesity and overweight: Fact sheet. In: WHO Media Centre [Internet]. 2020 [cited 8 Sep 2020]. Available: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
3. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003; 1: 1575–1579. https://doi.org/10.1046/j.1538-7836.2003.00279.x PMID: 12871293
4. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: The nurses’ health study. Am J Epidemiol. 1997; 145: 614–619. https://doi.org/10.1093/oxfordjournals.aje.a009158 PMID: 9098178
5. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982; 38: 41–44. https://doi.org/10.1210/jcem-54-2-254 PMID: 7033275
6. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, et al. C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors. Atherosclerosis. 2000; 149: 139–150. https://doi.org/10.1016/s0021-9150(99)00312-3 PMID: 10704625
7. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115: 1111–1119. https://doi.org/10.1172/JCI25102 PMID: 15864338
8. Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: All immune cells on the stage. Trends in Molecular Medicine. Elsevier Current Trends; 2013. pp. 487–500. https://doi.org/10.1016/j.molmed.2013.05.001 PMID: 23746697
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796–1808. https://doi.org/10.1172/JCI19246 PMID: 14679176
10. Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014; 20: 614–625. https://doi.org/10.1016/j.cmet.2014.08.010 PMID: 25242226
11. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metabolism. Cell Press; 2011. pp. 11–22. https://doi.org/10.1016/j.cmet.2010.12.008 PMID: 21195345
12. Furuya DT, Pololetti AC, Favaro RR, Martins JO, Zorn TMT, Machado UF. Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice. Metabolism. 2010; 59: 395–399. Available: https://www.ncbi.nlm.nih.gov/pubmed/19800637 https://doi.org/10.1016/j.metabol.2009.08.011 PMID: 19800637
Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017; 127: 83–93. https://doi.org/10.1172/JCI88884 PMID: 28045401

Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016; 39: S244–S252. https://doi.org/10.2337/dcS15-3015 PMID: 27440839

Donath MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nature Reviews Drug Discovery. Nature Publishing Group; 2014. pp. 465–476. https://doi.org/10.1038/nrd4275 PMID: 24854413
34. Lutz TA. Considering our methods: Methodological issues with rodent models of obesity and appetite research. Physiol Behav. 2018; 192: 182–187. https://doi.org/10.1016/j.physbeh.2018.02.026 PMID: 29454067
35. Blüher M. Metabolically healthy obesity. Endocrine Reviews. Endocrine Society; 2020. pp. 405–420. https://doi.org/10.1210/endre/bnaa004 PMID: 32128581
36. Lamichhane R, Pandeya PR, Lee K-H, Kim S-G, Devkota HP, Jung H-J. Anti-Adipogenic and Anti-Inflammatory Activities of (−)-epi-Osmundalactone and Angiopteroside from Angiopterus helleriana C. Presl. Molecules. 2020; 25: 1337. https://doi.org/10.3390/molecules25061337 PMID: 32183470
37. Mukherjee A, Mukherjee S, Biswas J, Roy M. Review Article Phytochemicals in obesity control. IntJCurrMicrobiolAppSci. 2015. Available: http://www.ijcmas.com
38. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-Lipoxigenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity. 2009; 17: 1657–1663. https://doi.org/10.1038/oby.2009.192 PMID: 19521344
39. Wang Y, Tang B, Long L, Luo P, Xiang W, Li X, et al. Improvement of obesity-associated disorders by a small-molecule drug targeting mitochondria of adipose tissue macrophages. Nat Commun. 2021; 12: 1–16. https://doi.org/10.1038/s41467-020-20315-9 PMID: 33397994
40. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10: 89. https://doi.org/10.1186/s13643-021-01626-4 PMID: 33781348
41. Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYR-CLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014; 14. https://doi.org/10.1186/1471-2288-14-43 PMID: 24667063
42. Nascimento SS da C, de Queiroz JLC, de Medeiros AF, de Franca Nunes AC, Piuzvezam G, Maciel BLL, et al. What are the mechanisms of action of anti-inflammatory agents in adipose tissue?: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100: e24677. https://doi.org/10.1097/md.00000000000024677 PMID: 33663077
43. Ouzzani M, Hammad y H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016; 5: 1–10. https://doi.org/10.1186/s13643-016-0384-4 PMID: 27919275
44. Zaugg H, West RE, Tateishi I, Randall DL. Mendelecy: Creating communities of scholarly inquiry through research collaboration. TechTrends. 2011; 55: 32–36. https://doi.org/10.1007/s11528-011-0467-y
45. Hsieh P-S, Jin J-S, Chiang C-F, Chan P-C, Chen C-H, Shih K-C. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring). 2009; 17: 1150–1157. Available: https://www.ncbi.nlm.nih.gov/pubmed/19247274 https://doi.org/10.1038/oby.2008.674 PMID: 19247274
46. Ma L, Liu T-W, Wallig MA, Dobrucki IT, Dobrucki LW, Nelson ER, et al. Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers. ACS Nano. 2016; 10: 6952–6962. Available: http://dx.doi.org/10.1021/acsnano.6b02878 PMID: 27281538
47. Ndisang JF, Jadhav A. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes. Diabetes Obes Metab. 2013; 15: 1029–1039. Available: https://doi.org/10.1111/dom.12130 PMID: 23731386
48. Castro GMMA, Passos TS, Nascimento SS da C, Medeiros I, Araújo NK, Maciel BLL, et al. Gelatin nanoparticles enable water dispersibility and potentize the antimicrobial activity of Buriti (Mauritia flexuosa) oil. BMC Biotechnol. 2020; 20: 55. https://doi.org/10.1186/s12896-020-00649-4 PMID: 33067511
49. Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, et al. SGLT2 Inhibition by Empaglifloz in Protein Kinase Activation. Nutrients. 2018; 10: 1204. Available: https://doi.org/10.3390/nu10091204 PMID: 30200432
53. Fenni S, Hammou H, Astier J, Bonnet L, Karkeni E, Couturier C, et al. Lycopene and tomato powder supplementation similarly inhibit high-fat diet induced obesity, inflammatory response, and associated metabolic disorders. Mol Nutr Food Res. 2017; 61. Available: https://www.ncbi.nlm.nih.gov/pubmed/28267248

54. Abu Bakar MH, Shariff KA, Tan JS, Lee LK. Celastrol attenuates inflammatory responses in adipose tissues and improves skeletal muscle mitochondrial function in high fat diet-induced obese rats via up-regulation of AMPK/SIRT1 signaling pathways. Eur J Pharmacol. 2020; 883: 173371. https://doi.org/10.1016/j.ejphar.2020.173371 PMID: 32712089

55. Alsaggar M, Bdour S, Ababneh Q, El-Elimat T, Qinna N, Alzoubi KH. Silibinin attenuates adipose tissue inflammation and reverses obesity and its complications in diet-induced obesity model in mice. BMC Pharmacol Toxicol. 2020; 21: 1–8. https://doi.org/10.1186/s40360-020-00385-8 PMID: 31973745

56. Han YB, Tian M, Wang XX, Fan DH, Li WZ, Wu F, et al. Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating IncRNA Gomafu. Int Immunopharmacol. 2020; 86: 106741. https://doi.org/10.1016/j.intimp.2020.106741 PMID: 32650294

57. Choi Y, Kim Y, Park S, Lee KW, Park T. Indole-3-carbinol prevents diet-induced obesity through modulation of multiple genes related to adipogenesis, thermogenesis or inflammation in the visceral adipose tissue of mice. J Nutr Biochem. 2012; 23: 1732–1739. Available: https://doi.org/10.1016/j.jnutbio.2011.12.005 PMID: 22569347

58. Ma L, Ni Y, Hu L, Zhao Y, Zheng L, Yang S, et al. Spermidine ameliorates high-fat diet-induced hepatic steatosis and adipose tissue inflammation in preexisting obese mice. Life Sci. 2021; 265: 118739. https://doi.org/10.1016/j.lfs.2020.118739 PMID: 33186567

59. Wei W, Hu M, Huang J, Yu S, Li X, Li Y, et al. Anti-obesity effects of DHA and EPA in high-fat fed-insulin resistant mice. Food Funct. 2021; 12: 1614–1625. Available: https://doi.org/10.1039/d0fo02448a PMID: 34748356

60. Cho S, Choi Y, Park S, Park T. Carvacrol prevents diet-induced obesity by modulating gene expressions involved in adipogenesis and inflammation in mice fed with high-fat diet. J Nutr Biochem. 2012; 23: 192–201. Available: https://doi.org/10.1016/j.jnutbio.2010.11.016 PMID: 21447440

61. Lee HJ, Jung H, Cho L, Lee K, Kwak H-K, Hwang KT. Dietary Black Raspberry Seed Oil Ameliorates Inflammatory Activities in db/db Mice. Lipids. 2016; 51: 715–727. Available: https://www.ncbi.nlm.nih.gov/pubmed/27165261 https://doi.org/10.1017/s11745-016-4159-4 PMID: 27165261

62. Fenni S, Hammou H, Astier J, Bonnet L, Karkeni E, Couturier C, et al. Lycopene and tomato powder supplementation similarly inhibit high-fat diet induced obesity, inflammatory response, and associated metabolic disorders. Mol Nutr Food Res. 2017; 61. Available: https://www.ncbi.nlm.nih.gov/pubmed/28267248

63. Oliveira V, Marinho R, Vitorino D, Santos GA, Dragoanu N, et al. Diets containing ω3 fatty acids rescues obese mice from insulin resistance. Endocrinology. 2015; 156: 4033–4046. Available: https://doi.org/10.1210/en.2014-1880 PMID: 26280128

64. Ye L, Liang S, Guo C, Yu X, Zhao J, Zhang H, et al. Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance. Life Sci. 2016; 166: 82–91. Available: https://www.ncbi.nlm.nih.gov/pubmed/27702567 https://doi.org/10.1016/j.lfs.2016.09.025 PMID: 27702567

65. Gao M, Ma Y, Liu D. Rutin suppresses palmitic acids-triggered inflammation in macrophages and blocks high fat diet-induced obesity and fatty liver in mice. Pharm Res. 2013; 30: 2940–2950. Available: https://doi.org/10.1007/s11095-013-1125-1 PMID: 23783345

66. Veeramani C, Alsaif MA, Al-Numair KS. Lavatera critica controls systemic insulin resistance by ameliorating adipose tissue inflammation and oxidative stress using bioactive compounds identified by GC–MS. Biomed Pharmacother. 2018; 106: 183–191. Available: https://www.sciencedirect.com/science/article/pii/S0753734018305055

67. Yang SJ, Choi JM, Park SE, Rhee EJ, Lee WY, Oh KW, et al. Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. J Nutr Biochem. 2015; 26: 234–240. Available: https://www.ncbi.nlm.nih.gov/pubmed/25498547 https://doi.org/10.1016/j.jnutbio.2014.10.010 PMID: 25498547

68. Ying W, Kanamori S, Chang C-A, Nair V, Safe S, Bazer FW, et al. Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulating macrophage polarization. Ziesel G, editor. PLoS One. 2014; 9: e98835. https://doi.org/10.1371/journal.pone.0098835 PMID: 24905566
70. Zhou J, Xu G, Ma S, Li F, Yuan M, Xu H, et al. Catalpol ameliorates high-fat diet-induced insulin resistance and adipose tissue inflammation by suppressing the JNK and NF-κB pathways. Biochem Biophys Res Commun. 2015; 467: 853–858. Available: https://www.ncbi.nlm.nih.gov/pubmed/26474703 https://doi.org/10.1016/j.bbrc.2015.10.054 PMID: 26474703

71. Subramanian G, Shanthugamprerna D, Subramani R, Muthuswamy K, Ponnusamy V, Tanka K, et al. Anti-Obesity Effect of T. Chebula Fruit Extract on High Fat Diet Induced Obese Mice: A Possible Alternative Therapy. Mol Nutr Food Res. 2021; 65: 1–8. https://doi.org/10.1002/mnfr.202001224 PMID: 33754444

72. yan Yu Y, chao Cui S, nan Zheng T, jian Ma H, fu Xie Z, wen Jiang H, et al. Sarsasapogenin improves adipose tissue inflammation and ameliorates insulin resistance in high-fat diet-fed C57BL/6J mice. Acta Pharmacol Sin. 2021, 42: 272–281. https://doi.org/10.1038/s41401-020-0427-1 PMID: 32699264

73. Bashir S, Sharma Y, Elahi A, Khan F. Amelioration of obesity-associated inflammation and insulin resistance in c57bl/6 mice via macrophage polarization by fish oil supplementation. J Nutr Biochom. 2016; 33: 82–90. Available: https://www.ncbi.nlm.nih.gov/pubmed/27260471 https://doi.org/10.1016/j.jnutbio.2016.02.011 PMID: 27260471

74. Bettaieb A, Cremonini E, Kang H, Kang J, Haj FG, Oteiza PI. Anti-inflammatory actions of (+)-epicatechin in the adipose tissue of obese mice. Int J Biochem Cell Biol. 2016; 81: 383–392. https://doi.org/10.1016/j.biocel.2016.08.044 PMID: 27592457

75. Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr Biochom. 2012; 23: 349–360. Available: https://doi.org/10.1016/j.jnutbio.2010.12.013 PMID: 21543211

76. Kwon OJ, Noh JW, Lee BC. Mechanisms and effect of coptidis rhizoma on obesity-induced inflammation: In silico and in vivo approaches. Int J Mol Sci. 2021; 22. https://doi.org/10.3390/jms22158075 PMID: 34360840

77. Lee JM, Choi SS, Park MH, Jiang H, Lee YH, Khim KW, et al. Broussonetia papyrifera root bark extract exhibits anti-inflammatory effects on adipose tissue and improves insulin sensitivity potentially via AMPK activation. Nutrients. 2020; 12. https://doi.org/10.3390/nu12030773 PMID: 32183397

78. Perdicaro DJ, Rodriguez Lanzi C, Gambarte Tudela J, Miatello RM, Oteiza PI, Vazquez Prieto MA. Quercetin attenuates adipose hypertrophy, in part through activation of adipogenesis in rats fed a high-fat diet. J Nutr Biochom. 2020; 79: 108352. https://doi.org/10.1016/j.jnutbio.2020.108352 PMID: 32145471

79. Ramalho T, Pahlavani M, Kalupahana N, Wijayatunga N, Ramalingam L, Jancar S, et al. Eicosapentaenoic acid regulates inflammatory pathways through modulation of transcripts and mirna in adipose tissue of obese mice. Biomolecules. 2020; 10: 1–15. https://doi.org/10.3390/biom10091292 PMID: 32906847

80. Dinh CHL, Szabo A, Camer D, Yu Y, Wang H, Huang X-F. Bardoxolone methyl prevents fat deposition and inflammation in the visceral fat of mice fed a high-fat diet. Chem Biol Interact. 2015: 229: 1–8. Available: https://www.ncbi.nlm.nih.gov/pubmed/25637688 https://doi.org/10.1016/j.cbi.2015.01.025 PMID: 25637688

81. Wang X, He G, Peng Y, Zhong W, Wang Y, Zhang B. Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway. Sci Rep. 2015; 5: 12676. https://www.ncbi.nlm.nih.gov/pubmed/26234821 https://doi.org/10.1038/srep12676 PMID: 26234821

82. Bak E-J, Choi K-C, Jang S, Woo G-H, Yoon H-G, Na Y, et al. Licochalcone F alleviates glucose tolerance and chronic inflammation in diet-induced obese mice through Akt and p38 MAPK. Cln Nutr. 2016; 35: 414–421. Available: https://www.ncbi.nlm.nih.gov/pubmed/25833886 https://doi.org/10.1016/j.clnu.2015.03.005 PMID: 25833886

83. Gambaro SE, Zubiria MG, Giordano AP, Portales AE, Alzamendi A, Rumbo M, et al. “Sexpin improves adipose tissue inflammation and macrophage recruitment in obese mice.” Biochim Biophys Acta—Mol Cell Biol Lipids. 2020; 1865: 158700. https://doi.org/10.1016/j.bbalip.2020.158700 PMID: 32201217

84. Chen C, Han X, Dong P, Li Z, Yanagita T, Xue C, et al. Sea cucumber saponin liposomes ameliorate obesity-induced inflammation and insulin resistance in high-fat diet-fed mice. Food Funct. 2018; 9: 861–870. Available: https://doi.org/10.1039/c7fo01599b PMID: 29292463

85. Squadrino F, Rottura M, Irrera N, Minutoli L, Bitto A, Barbieri MA, et al. Anti-obesity drug therapy in clinical practice: Evidence of a poor prescriptive attitude. Biomed Pharmacother. 2020; 128: 110320. https://doi.org/10.1016/j.biopha.2020.110320 PMID: 32502842

86. Carvalho FMC, Lima VCO, Costa IS, Luz ABS, Ladd FVL, Serquiz AC, et al. Anti-TNF-α agent tamarind kunitz trypsin inhibitor improves lipid profile of wistar rats presenting dyslipidemia and diet-induced obesity regardless of PPARY induction. Nutrients. 2019; 11: 512. https://doi.org/10.3390/nu11030512 PMID: 30818882
87. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang Z V., et al. Adipocyte Inflammation is Essential for Healthy Adipose Tissue Expansion and Remodeling. Cell Metab. 2014; 20: 103. https://doi.org/10.1016/j.cmet.2014.05.005 PMID: 24930973

88. Zhu Q, An YA, Kim M, Zhang Z, Zhao S, Zhu Y, et al. Suppressing adipocyte inflammation promotes insulin resistance in mice. Mol Metab. 2020; 39. https://doi.org/10.1016/j.molmet.2020.101010 PMID: 32408016

89. Salinero AE, Anderson BM, Zuloaga KL. Sex differences in the metabolic effects of diet-induced obesity vary by age of onset. Int J Obes 2018 425. 2018; 42: 1088–1091. https://doi.org/10.1038/s41366-018-0023-3 PMID: 29463918

90. de Moura e Dias M, dos Reis SA, da Conceição LL, Sedyama CMN de O, Pereira SS, de Oliveira LL, et al. Diet-induced obesity in animal models: points to consider and influence on metabolic markers. Diabetol Metab Syndr. 2021; 13: 1–14. https://doi.org/10.1186/S13098-021-00647-2/TABLES/3

91. Park JH, Yoo Y, Cho M, Lim J, Lindroth AM, Park YJ. Diet-induced obesity leads to metabolic dysregulation in offspring via endoplasmic reticulum stress in a sex-specific manner. Int J Obes 2018 422. 2017; 42: 244–251. https://doi.org/10.1038/ijo.2017.203 PMID: 28811650

92. Stubbins RE, Najjar K, Holcomb VB, Hong J, Núñez NP. Estrogen alters adipocyte biology and protects female mice from adipocyte inflammation and insulin resistance. Diabetes Obes Metab. 2012; 14: 58. https://doi.org/10.1111/J.1463-1326.2011.01488.X

93. Ishikawa A, Wada T, Nishimura S, Ito T, Okekawa A, Onogi Y, et al. Estrogen regulates sex-specific localization of regulatory T cells in adipose tissue of obese female mice. PLoS One. 2020; 15. https://doi.org/10.1371/journal.pone.0230885 PMID: 32240221